

## Half year update on the DBV Technologies liquidity agreement

Montrouge, France, July 11<sup>th</sup> - As per the liquidity contract granted by DBV TECHNOLOGIES to NATIXIS, the following assets appeared on the liquidity account as at June 30th, 2016:

- 3,883 DBV TECHNOLOGIES shares
- EUR 1,279,638

At the last half-year DBV TECHNOLOGIES liquidity contract statement as at December 31st, 2015, the following resources were listed in the liquidity account:

- 3,898 DBV TECHNOLOGIES shares
- EUR 1,383,821

Under the terms of the liquidity contract, pursuant to Article 12, it is recalled that the following resources have been added as of December 15, 2014:

- EUR 600,000

It is specified that at the implementation of the contract the following resources were listed in the liquidity account:

- 0 DBV TECHNOLOGIES share
- EUR 300,000.00

### About DBV Technologies

DBV Technologies developed Viaskin<sup>®</sup>, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<sup>®</sup>, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: [www.dbv-technologies.com](http://www.dbv-technologies.com)



### **DBV Technologies Contact**

#### **Susanna Mesa**

Senior Vice President, Strategy

+1 212-271-0861

[susanna.mesa@dbv-technologies.com](mailto:susanna.mesa@dbv-technologies.com)

### **Media Contacts**

#### **Erinn White, Centron PR**

+1 646-722-8822

[ewhite@centronpr.com](mailto:ewhite@centronpr.com)

### **Media Contacts, Europe**

#### **Caroline Carmagnol, Alize RP – Relation Presse**

+33 (0)6 64 18 99 59

[caroline@alizerp.com](mailto:caroline@alizerp.com)